^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Noradrenaline uptake inhibitor

    Related drugs:
    25d
    O-GlcNAcylation of SPOP regulates colorectal cancer progression and ferroptosis by mediating β-catenin degradation. (PubMed, Cell Death Discov)
    Combined treatment with the SPOP-targeted drug maprotiline and a ferroptosis inducer has synergistic antitumor efficacy in CRC cells and xenografts. Our study reveals the multifaceted function of SPOP in CRC, and the activation of SPOP may be a feasible strategy to increase the sensitivity of CRC to ferroptosis inducers.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SPOP (Speckle Type BTB/POZ Protein) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    maprotiline
    1m
    National Pregnancy Registry for Psychiatric Medications (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Massachusetts General Hospital
    Trial completion date • Trial primary completion date
    9ms
    Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder (clinicaltrials.gov)
    P4, N=84, Recruiting, All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting --> Recruiting
    Enrollment open
    10ms
    Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder (clinicaltrials.gov)
    P4, N=84, Not yet recruiting, All India Institute of Medical Sciences, Bhubaneswar
    New P4 trial
    1year
    Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer. (PubMed, Adv Sci (Weinh))
    By applying Mnet-DRI to PD-L1, maprotiline (MAP), an antidepressant drug is repurposed, as a potential PD-L1 modifier for colorectal and lung cancers. Experimental validation revealed that MAP reduced PD-L1 expression by targeting E3 ubiquitin ligase speckle-type zinc finger structural protein (SPOP), and the combination of MAP and anti-CTLA4 in vivo significantly enhanced the antitumor effect, providing a new alternative for the clinical treatment of colorectal and lung cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • SPOP (Speckle Type BTB/POZ Protein)
    |
    PD-L1 expression
    |
    maprotiline
    1year
    PSD-AOFC: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (clinicaltrials.gov)
    P4, N=60, Completed, All India Institute of Medical Sciences, Bhubaneswar | Recruiting --> Completed
    Trial completion
    2years
    Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma. (PubMed, Curr Mol Pharmacol)
    Our research findings suggest that maprotiline enhances the antitumour immune response in mouse melanoma by inhibiting PD-L1 expression. This study may discover a new PD-L1 inhibitor, providing a novel therapeutic option for the clinical treatment of tumours.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    2years
    National Pregnancy Registry for Psychiatric Medications (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Massachusetts General Hospital | N=2500 --> 5000
    Enrollment change
    5years
    Managing menopausal symptoms after cancer. (PubMed, Climacteric)
    Non-hormonal methods to manage vasomotor symptoms include cognitive behavioral therapy, hypnosis, selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, clonidine, and gabapentin...Management of menopausal symptoms after cancer may be challenging and should include information about induced menopause and possible symptoms as well as available treatments. Management then requires a holistic and multidisciplinary approach with individualized care.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    over5years
    Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer via stimulation of noradrenaline pathway and its antitumor effects. (PubMed, Pain)
    Meanwhile, atipamezole did not inhibit the antitumor effects of duloxetine in vitro and in vivo. Therefore, our results indicate that duloxetine mainly improves cancer-associated pain by enhancement of the noradrenergic pathway rather than the serotoninergic pathway, while duloxetine modulates antitumor effects on PDAC without involvement of the noradrenergic pathway.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)